Novartis drug Zykadia receives FDA Priority Review for first-line use in patients with ALK+ metastatic NSCLC
- Details
- Category: Novartis
Novartis today announced that the US Food and Drug Administration (FDA) accepted the Company's supplemental New Drug Application (sNDA) for filing, and granted Priority Review for the expanded use of Zykadia® (ceritinib) as a first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.
Another record year for Bayer - good progress with the acquisition of Monsanto
- Details
- Category: Bayer
Bayer had a very successful year in 2016, both strategically and operationally. Sales of the Bayer Group increased in 2016 by 1.5 percent (Fx & portfolio adj. 3.5 percent) to EUR 46,769 million (2015: EUR 46,085 million). EBITDA before special items advanced by 10.2 percent to EUR 11,302 million (2015: EUR 10,256 million). EBIT rose by 12.8 percent to EUR 7,042 million (2015: EUR 6,241 million) after special charges of EUR 1,088 million (2015: EUR 819 million).
Bristol-Myers Squibb appoints three new independent directors
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has appointed Robert J. Bertolini, Matthew W. Emmens and Theodore R. Samuelsto its Board of Directors, effective immediately. In connection with these appointments, the Board will temporarily expand to 14 directors until the 2017 Annual Meeting, to be held on May 2, 2017.
AstraZeneca enters agreement with TerSera Therapeutics for Zoladex in the US and Canada
- Details
- Category: AstraZeneca
AstraZeneca today announced that it has entered into an agreement with TerSera Therapeutics LLC (TerSera) for the commercial rights to Zoladex (goserelin acetate implant) in the US and Canada. Zoladex is an injectable luteinising hormone-releasing hormone agonist, used to treat prostate cancer, breast cancer and certain benign gynaecological disorders.
Siliq (brodalumab) approved by the US FDA for adult patients with moderate-to-severe plaque psoriasis
- Details
- Category: AstraZeneca
AstraZeneca's partner Valeant Pharmaceuticals today announced that the US Food and Drug Administration (FDA) has approved Siliq (brodalumab) injection for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies.
Boehringer Ingelheim and Weill Cornell Medicine announce new collaboration to discover next generation COPD treatments
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim today announced a collaboration with Weill Cornell Medicine to identify new treatment approaches for chronic obstructive pulmonary disease (COPD) in order to develop novel treatments that could possibly halt or even reverse the progression of the disease process.
Phase III COMPASS study with Bayer's rivaroxaban (Xarelto®) shows overwhelming efficacy and meets primary endpoint early
- Details
- Category: Bayer
Bayer AG and its cooperation partner Janssen Research & Development, LLC have announced that the Phase III trial COMPASS evaluating the efficacy and safety of rivaroxaban (Xarelto®) for the prevention of major adverse cardiac events (MACE) including cardiovascular death, myocardial infarction and stroke in patients with coronary artery disease (CAD) or peripheral artery disease (PAD) has met its primary endpoint ahead of time.
More Pharma News ...
- Relationship expert teams up with Pfizer to address intimacy and relationship issues for people living with chronic diseases
- Cladribine tablets significantly reduced brain atrophy in patients with multiple sclerosis
- Regorafenib granted priority review in the U.S. for second-line treatment of liver cancer
- Amgen announces Repatha® (evolocumab) significantly reduced the risk of cardiovascular events in FOURIER outcomes study
- Roche reports good results in 2016
- Pfizer reports fourth-quarter and full-year 2016 results
- Novo Nordisk enters collaboration with University of Oxford on type 2 diabetes and invests GBP 115m in new research centre